{
  "id": 20025157,
  "title": "Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?",
  "url": "https://urgent.news/2026/11/14/novo-nordisk-vs-pfizer-does-a-weight-loss-or-cancer-focused-pharma-20025157",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-14T17:32:01.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/novo-nordisk-vs-pfizer-does-weight-loss-or-cancer-focused-pharma-stock-make-better-buy"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsNovo Nordisk A/S maintains a leading position in the high-growth obesity and diabetes treatment markets.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?",
        "url": "https://urgent.news/2026/11/14/novo-nordisk-vs-pfizer-does-a-weight-loss-or-cancer-focused-pharma",
        "published": "2026-11-14T17:12:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}